Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the safety and efficacy of 3% LTX-109 for nasal decolonization of Staphylococcus aureus has completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Infections
• Staphylococcus Aureus Nasal Colonization

Drugs mentioned

• 3% LTX-109 (LTX-109)

Snippet

Sponsor: Pharma Holdings AS | Conditions: Nasal Decolonization of Staphylococcus Aureus | Phase 1, Phase 2 | Status: COMPLETED